
Opinion|Videos|December 22, 2023
Monitoring Patients on Treatment for MF
Author(s)Aaron T. Gerds, MD, MS
Aaron Gerds, MD, MS, explains that myelofibrosis patients on JAK inhibitors need regular monitoring of blood counts, liver enzymes, and cardiac events to check for reactivation.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
3
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
4
Illuminating the Sequence of Third-Line Therapies in Metastatic CRC
5







































